Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Vera Therapeutics is using equity inducement grants to attract six new hires, with options and RSUs vesting over four years.

Rhea-AI Summary

Vera Therapeutics (VERA) granted inducement equity awards on September 1, 2026 to six new employees under its 2024 Inducement Plan, in line with Nasdaq Listing Rule 5635(c)(4).

The grants include non-qualified stock options to purchase 61,500 Class A shares at an exercise price of $34.23 per share and RSUs covering 30,750 Class A shares. Options vest over four years, with 25% after one year and the remainder monthly over 36 months. RSUs vest 25% annually over four years from either August 20 or November 20, 2026, depending on employee start date, subject to continued service.

Positive

• Equity awards to six new hires may aid recruitment and retention
• Vesting over four years aligns employee incentives with longer-term shareholder value

Negative

• 92,250 new equity awards (options plus RSUs) add future dilution for existing shareholders
• Stock-based compensation at a $34.23 option strike may increase ongoing compensation expense

Argus Sep 8 session 2 alerts

-1.70% close to close 0.8x rel. volume Open Argus

Details

News Market Reaction – VERA

$2.62B Mkt Cap at Peak Alert

On Sep 8, the first trading day after this news, VERA closed 1.70% below the previous close. Our momentum scanner recorded 2 alerts in the available session data.

Data tracked by StockTitan Argus for the Sep 8 session.

Key Figures

Stock options: 61,500 shares Restricted stock units: 30,750 shares Recipients: 6 new employees +5 more

Stock options

61,500 shares

Inducement awards granted September 1, 2026

Restricted stock units

30,750 shares

Inducement awards granted September 1, 2026

Recipients

6 new employees

September 1, 2026 grants

Exercise price

$34.23 per share

Equal to closing trading price on September 1, 2026

Option vesting

4 years

Subject to continued service

Initial option vesting

25%

Underlying shares vest on the first anniversary

Monthly option vesting

36 months

Remaining option shares vest monthly thereafter

RSU annual vesting

25%

Vests on each anniversary over four years

Historical Context

5 past events · Latest: Sep 01

5 events

1. Sep 01

   Investor conference notice

   24h Move

   +0.5%

   Announced participation in two upcoming healthcare investor conferences.

2. Aug 10

   Second-quarter earnings

   24h Move

   -4.0%

   Reported accelerated approval and commercial launch alongside quarterly financial results.

3. Aug 07

   Inducement equity grants

   24h Move

   -4.0%

   Granted options and RSUs to new regulatory leadership and employees.

4. Jul 10

   Inducement equity grants

   24h Move

   -1.2%

   Granted options and RSUs to eight new employees.

5. Jul 09

   Leadership transition

   24h Move

   +0.1%

   Announced chief regulatory officer succession and planned retirement.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

non-qualified stock options, restricted stock units, nasdaq listing rule 5635(c)(4)

3 terms

non-qualified stock options financial

"granted inducement awards consisting of non-qualified stock options to purchase"

Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.

restricted stock units financial

"and restricted stock units (RSUs) underlying 30,750 shares"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BRISBANE, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on September 1, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 61,500 shares of Class A common stock and restricted stock units (RSUs) underlying 30,750 shares of Class A common stock to six (6) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan). The Compensation Committee approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Each stock option granted on September 1, 2026 has an exercise price per share equal to $34.23, Vera Therapeutics’ closing trading price on September 1, 2026. Each stock option will vest over four years, with 25% of the underlying shares vesting on the first anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employee’s continued service relationship with Vera Therapeutics through the applicable vesting dates. Each of the RSU awards will vest over four years, with 25% of the underlying shares vesting on each anniversary of either August 20 or November 20, 2026, depending on the start date of the new employee, subject to the new employee’s continued service relationship with Vera Therapeutics through the applicable vesting dates. The awards are subject to the terms and conditions of the Inducement Plan and the terms and conditions of an applicable award agreement covering the grant.

About Vera Therapeutics
Vera Therapeutics is a commercial-stage biotechnology company focused on the pursuit of truth in science to transform medicine in autoimmune disease, starting with the kidney. Vera Therapeutics’ flagship commercial product is TRUTAKNA^TM (atacicept-vymj), a B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL) inhibitor. Vera Therapeutics is evaluating multiple diseases where the reduction of autoantibodies through inhibition of BAFF and APRIL may prove clinically meaningful. Vera Therapeutics was founded in 2016 and is based in Brisbane, California. To learn more, visit www.veratx.com.

For more information, please contact:

Investor Contact:
Joshua Qin
Vera Therapeutics
650-360-6978
ir@veratx.com

Media Contact:
Debra Charlesworth
Vera Therapeutics
415-854-8051
corporatecommunications@veratx.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity inducement grants did Vera Therapeutics (VERA) announce on September 4, 2026?

Vera Therapeutics announced inducement equity awards granted on September 1, 2026 to six new employees, consisting of non-qualified stock options for 61,500 Class A shares and RSUs covering 30,750 Class A shares under its 2024 Inducement Plan.

What is the exercise price of the new Vera Therapeutics (VERA) stock options?

Each non-qualified stock option granted on September 1, 2026 has an exercise price of $34.23 per share, equal to Vera Therapeutics’ closing trading price on that date.

How do the Vera Therapeutics (VERA) inducement stock options vest?

The stock options vest over four years. 25% of the underlying shares vest on the first anniversary of the vesting commencement date, with the remaining shares vesting monthly over the following 36 months, subject to continued service.

What is the vesting schedule for the RSUs in the Vera Therapeutics (VERA) inducement grants?

Each RSU award vests over four years, with 25% of the underlying shares vesting on each anniversary of either August 20 or November 20, 2026, depending on the employee’s start date, subject to continued service.

Under which plan were the Vera Therapeutics (VERA) inducement awards granted?

The inducement stock options and RSUs were granted under the Vera Therapeutics 2024 Inducement Plan, with each award also governed by a specific award agreement.

Why were the Vera Therapeutics (VERA) inducement awards granted under Nasdaq Listing Rule 5635(c)(4)?

The Compensation Committee approved these equity awards as an inducement material to the new employees’ employment, in accordance with Nasdaq Listing Rule 5635(c)(4), which permits inducement grants without prior shareholder approval under specified conditions.